Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Study ID
- NCT07599449
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- COVID - 19
- Influenza
- Influenza -Like Illness
- Metapneumovirus Infection
- RSV Infections
- Respiratory Tract Infections (RTI)
- Rhinovirus Infection
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- saliva sampling — DIAGNOSTIC_TESTBased on the protocol, physicians perform either a nasopharyngeal swab or saliva collection on included patients. The method is determined by scientific data and epidemiological constraints, not by the patient. Saliva collection: The physician oversees the collection during the visit using the provided kit (pipette, tube, etc.). Depending on constraints, the patient may perform the collection at home if agreed upon. If the patient is unable to self-collect (e.g., infants, facial paralysis), the physician collects the saliva directly from under the tongue using the pipette.
- Nasopharyngeal swab — DIAGNOSTIC_TESTBased on the protocol, physicians perform either a nasopharyngeal swab or saliva collection on included patients. The method is determined by scientific data and epidemiological constraints, not by the patient. Nasopharyngeal sampling: During the consultation, the physician performs a deep nasal swab using the provided kit (FFP2 mask, swab, transport tube, absorbent, SafetyBag, and pre-paid envelope for partner labs).
Study Details
Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs). These viruses can cause epidemics of varying severity, requiring close monitoring to determine their circulation levels and adapt public health measures accordingly. In France, ARI surveillance relies on two networks: the Sentinelles network in primary care and the RENAL network in hospitals. The Sentinelles surveillance is conducted in collaboration with Santé publique France, the National Reference Center for Respiratory Infection Viruses (Institut Pasteur and Hospices Civils de Lyon), and the University of Corsica. As part of the virological surveillance of ARIs, Sentinelles physicians are asked to collect nasopharyngeal swabs or saliva samples from a sample of patients presenting with an ARI during their clinic visits. This surveillance makes it possible to identify respiratory viruses circulating in primary care (general practice and pediatrics), to describe confirmed cases for each of the circulating viruses, and to estimate the impact of each on general practice. This surveillance also allows for the evaluation of the effectiveness of vaccines against influenza and COVID-19.
Key Dates
- First listed
- May 20, 2026
- Start date
- May 15, 2026
- Status verified
- May 2026
- Primary completion
- May 15, 2031
- Completion
- May 20, 2031
Study Design
- Enrollment
- 25,000 participants (estimated)
Arms
- Arm: Individuals with an ARI consulting a GP or a private pediatrician in mainland France
Primary Outcome Measure
Proportion of acute respiratory infection (ARI) cases seen in private practice (general practice and pediatrics) that tested positive for influenza viruses (by type and subtype), SARS-CoV-2, RSV, rhinovirus, and metapneumovirus [ Time Frame: Baseline ]
Central Contacts
- Thierry BLANCHON, MD, PhD+33664846662
- Olivier STEICHEN, MD, PhD
Related Studies
- Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Influenza Immunization in Adults Over Age 75Recruiting · Johns Hopkins University · Baltimore, Maryland
- Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised PatientsPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
- Observational Digital Biomarker Discovery in Respiratory Virus Challenge StudiesRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland